The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Iron overload in thalassemia: different organs at different rates
Open accessAbstract
Thalassemic disorders lie on a phenotypic spectrum of clinical severity that depends on the severity of the globin gene mutation and coinheritance of other genetic determinants. Iron overload is associated with increased morbidity in both patients with transfusion-dependent thalassemia (TDT) and non–transfusion-dependent thalassemia (NTDT). The predominant mechanisms driving the process of iron loading include increased iron burden secondary to transfusion therapy in TDT and enhanced intestinal absorption secondary to ineffective erythropoiesis and hepcidin suppression in NTDT. Different organs are affected differently by iron overload in TDT and NTDT owing to the underlying iron loading mechanism and rate of iron accumulation. Serum ferritin measurement and noninvasive imaging techniques are available to diagnose iron overload, quantify its extent in different organs, and monitor clinical response to therapy. This chapter discusses the general approach to iron chelation therapy based on organ involvement using the available iron chelators: deferoxamine, deferiprone, and deferasirox. Other novel experimental options for treatment and prevention of complications associated with iron overload in thalassemia are briefly discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127
Borgna‐Pignatti, C., Rugolotto, S., Stefano, P. D., Zhao, H., Cappellini, M. D., Vecchio, G. C. D., Romeo, M. A., Forni, G. L., Gamberini, M. R., Ghilardi, R., et al. (2004) · PubMed · Cited by 1,119
Brittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S., Tucker, E. E., Allen, C. J., Farrell, D. E., & Harris, J. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409013310902 · Cited by 829
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717
Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major
Angelucci, E., Brittenham, G. M., McLaren, C. E., Ripalti, M., Baronciani, D., Giardini, C., Galimberti, M., Polchi, P., & Lucarelli, G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430503 · Cited by 607
Modell, B., Khan, M., Darlison, M., Westwood, M. A., Ingram, D., & Pennell, D. J. (2008) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-10-42 · Cited by 600
Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3512 · Cited by 445
Anderson, L. J., Westwood, M. A., Holden, S., Davis, B., Prescott, E., Wonke, B., Porter, J. B., Malcolm Walker, J., & Pennell, D. J. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05202.x · Cited by 414
Pennell, D. J., Udelson, J. E., Arai, A. E., Bozkurt, B., Cohen, A. R., Galanello, R., Hoffman, T. M., Kiernan, M. S., Lerakis, S., Piga, A., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829b2be6 · Cited by 394
Taher, A. T., Musallam, K. M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., Saned, M.-S., El-Chafic, A.-H., Fasulo, M. R., & Cappellini, M. D. (2010) · Blood · doi:10.1182/blood-2009-09-243154 · Cited by 392
Self-citationResults of Long-Term Iron-Chelating Therapy
Gabutti, V., & Piga, A. (2009) · Acta Haematologica · doi:10.1159/000203853 · Cited by 378
Anemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
Farmaki, K., Tzoumari, I., Pappa, C., Chouliaras, G., & Berdoukas, V. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07970.x · Cited by 252
Telfer, P. T., Prestcott, E., Holden, S., Walker, M., Hoffbrand, A. V., & Wonke, B. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02298.x · Cited by 240
Tanner, M. A., Galanello, R., Dessi, C., Smith, G. C., Westwood, M. A., Agus, A., Pibiri, M., Nair, S. V., Walker, J. M., & Pennell, D. J. (2008) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-10-12 · Cited by 238
Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57693 · Cited by 234 · cited 1×
“Longacting hepcidin analogs (minihepcidins) have thus been developed to suppress iron absorption and are currently being investigated.(57) If and when minihepcidins reach the clinical realm, they could be potentially used alone or in combination with ICT to control iron overload.”
BackgroundCappellini, M. D., Bejaoui, M., Agaoglu, L., Canatan, D., Capra, M., Cohen, A., Drelichman, G., Economou, M., Fattoum, S., Kattamis, A., et al. (2011) · Blood · doi:10.1182/blood-2010-11-316646 · Cited by 222
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice
Guo, S., Casu, C., Gardenghi, S., Booten, S., Aghajan, M., Peralta, R., Watt, A., Freier, S., Monia, B. P., & Rivella, S. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66969 · Cited by 222
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C. N., Andrews, N. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41717 · Cited by 220
How I treat transfusional iron overload
Hoffbrand, A. V., Taher, A., & Cappellini, M. D. (2012) · Blood · doi:10.1182/blood-2012-05-370098 · Cited by 207
Self-citationEfficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia
Pennell, D. J., Porter, J. B., Cappellini, M. D., El-Beshlawy, A., Chan, L. L., Aydinok, Y., Elalfy, M. S., Sutcharitchan, P., Li, C.-K., Ibrahim, H., et al. (2010) · Blood · doi:10.1182/blood-2009-04-217455 · Cited by 195
Self-citationDeferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial
Maggio, A., D'Amico, G., Morabito, A., Capra, M., Ciaccio, C., Cianciulli, P., Di Gregorio, F., Garozzo, G., Malizia, R., Magnano, C., et al. (2002) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.2002.0510 · Cited by 192
Physiology and pathophysiology of iron in hemoglobin-associated diseases
Coates, T. D. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.039 · Cited by 181
Delea, T. E., Edelsberg, J., Sofrygin, O., Thomas, S. K., Baladi, J., Phatak, P. D., & Coates, T. D. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01416.x · Cited by 180
Hepatocellular carcinoma in the thalassaemia syndromes
Borgna‐Pignatti, C., Vergine, G., Lombardo, T., Cappellini, M. D., Cianciulli, P., Maggio, A., Renda, D., Lai, M. E., Mandas, A., Forni, G., et al. (2004) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04732.x · Cited by 174
Ineffective erythropoiesis and regulation of iron status in iron loading anaemias
Camaschella, C., & Nai, A. (2016) · British Journal of Haematology · doi:10.1111/bjh.13820 · Cited by 172 · cited 1×
“Other erythroid factors, including growth differentiation factor and twistedgastrulation 1, have been previously considered but have not been shown to be upregulated in murine models of b-thalassemia.(9)”
BackgroundDeletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia
Nai, A., Pagani, A., Mandelli, G., Lidonnici, M. R., Silvestri, L., Ferrari, G., & Camaschella, C. (2012) · Blood · doi:10.1182/blood-2012-01-401885 · Cited by 161
Gene Therapy for β-Hemoglobinopathies
Cavazzana, M., Antoniani, C., & Miccio, A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.024 · Cited by 149
Taher, A. T., Porter, J. B., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakaş, Z., Lawniczek, T., et al. (2012) · Blood · doi:10.1182/blood-2012-02-412692 · Cited by 148
Self-citationPennell, D. J., Porter, J. B., Cappellini, M. D., Chan, L. L., El-Beshlawy, A. M., Aydınok, Y., Ibrahim, H. M., Li, C. K., Viprakasit, V., Elalfy, M. S., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.049957 · Cited by 141
Self-citationAngelucci, E., BARONCIANI, D., Lucarelli, G., Baldassarri, M., GALIMBERTI, M., Giardini, C., Martinelli, F., Polchi, P., Polizzi, V., Ripalti, M., et al. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb08412.x · Cited by 133
Growth Failure and Bony Changes Induced by Deferoxamine
Olivieri, N. F., Koren, G., Harris, J., Khattak, S., Freedman, M. H., Templeton, D. M., Bailey, J. D., & Reilly, B. J. (1992) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199221000-00007 · Cited by 129
Taher, A. T., Rassi, F. A. E., Isma’eel, H., Koussa, S., Inati, A. C., & Cappellini, M. D. (2008) · Haematologica · doi:10.3324/haematol.13098 · Cited by 125
Self-citationPennell, D. J., Porter, J. B., Piga, A. G., Lai, Y., El-Beshlawy, A. M., Belhoul, K., Elalfy, M. S., Yeşilipek, A., Kılınç, Y., Lawniczek, T., et al. (2014) · Blood · doi:10.1182/blood-2013-04-497842 · Cited by 123
Aydınok, Y., Kattamis, A., Cappellini, M. D., El-Beshlawy, A. M., Origa, R., Elalfy, M. S., Kılınç, Y., Perrotta, S., Karakaş, Z., Viprakasit, V., et al. (2015) · Blood · doi:10.1182/blood-2014-07-586677 · Cited by 88
on behalf of the Greek Haemoglobinopathies Study Group, Voskaridou, E., Ladis, V. A., Kattamis, A., Hasapopoulou, E., Economou, M. P., Kourakli, A., Maragkos, K., Kontogianni, K., Lafioniatis, S., et al. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1465-7 · Cited by 85
International survey of T2* cardiovascular magnetic resonance in -thalassemia major
Carpenter, J. P., Roughton, M., Pennell, D. J., & the Myocardial Iron in Thalassemia (MINT) Investigators (2013) · Haematologica · doi:10.3324/haematol.2013.083634 · Cited by 78
Aydınok, Y., Ülger, Z., Nart, D., Terzi, A., Cetiner, N., Ellis, G., Zimmermann, A., & Manz, C. (2007) · Haematologica · doi:10.3324/haematol.11414 · Cited by 77
Taher, A. T., Musallam, K. M., Wood, J. C., & Cappellini, M. D. (2009) · American Journal of Hematology · doi:10.1002/ajh.21626 · Cited by 77
Self-citationAessopos, A., Fragodimitri, C., Karabatsos, F., Hatziliami, A., Yousef, J., Giakoumis, A., Dokou, A., Gotsis, E. D., Berdoukas, V. A., & Karagiorga, M. (2007) · Haematologica · doi:10.3324/haematol.10455 · Cited by 76
Taher, A. T., Porter, J. B., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakaş, Z., Lawniczek, T., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1808-z · Cited by 74
Self-citationAydınok, Y., Porter, J. B., Piga, A. G., Elalfy, M. S., El-Beshlawy, A. M., Kılınç, Y., Viprakasit, V., Yeşilipek, A., Habr, D., Quebe‐Fehling, E., et al. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12487 · Cited by 73
Porter, J. B., Wood, J. C., Olivieri, N. F., Vichinsky, E. P., Taher, A. T., Neufeld, E. J., Giardina, P. J., Thompson, A. A., Moore, B., Evans, P., et al. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-38 · Cited by 57
Self-citationBrain magnetic resonance angiography in splenectomized adults with β-thalassemia intermedia
Musallam, K. M., Beydoun, A. A., Hourani, R. G., Nasreddine, W., Raad, R. A., Koussa, S., & Taher, A. T. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01706.x · Cited by 55
Self-citationViprakasit, V., Nuchprayoon, I., Chuansumrit, A., Torcharus, K., Pongtanakul, B., Laothamatas, J., Srichairatanakool, S., Pooliam, J., Supajitkasem, S., Suriyaphol, P., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23386 · Cited by 53
Calvaruso, G., Vitrano, A., Maggio, R. D., Lai, E., Colletta, G., Quota, A., Gerardi, C., Rigoli, L. C., Sacco, M., Pitrolo, L., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24024 · Cited by 48
Asian Immigration and Public Health in California: Thalassemia in Newborns in California
Lorey, F. (2000) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200011000-00024 · Cited by 47
Musallam, K. M., Cappellini, M. D., & Taher, A. T. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1944 · Cited by 42
Self-citationMamtani, M., & Kulkarni, H. R. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07122.x · Cited by 42
Taher, A. T., Cappellini, M. D., Aydınok, Y., Porter, J. B., Karakaş, Z., Viprakasit, V., Siritanaratkul, N., Kattamis, A., Wang, C., Zhu, Z., et al. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.11.002 · Cited by 30
Self-citationViprakasit, V., Gattermann, N., Lee, J. W., Porter, J. B., Taher, A. T., Habr, D., Martin, N., Domokos, G., & Cappellini, M. D. (2013) · Europe PMC (PubMed Central) · doi:10.2450/2012.0012-12 · Cited by 28
Self-citationInvestigational drugs in phase I and phase II clinical trials for thalassemia
Motta, I., Scaramellini, N., & Cappellini, M. D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1335709 · Cited by 27
Cited by
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease
Fang, X., Ardehali, H., Min, J., & Wang, F. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00735-4 · Cited by 1,081
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Tuo, Y., Li, Y., Li, Y., Ma, J., Yang, X., Wu, S., Jin, J., & He, Z. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102619 · Cited by 283
A role of PIEZO1 in iron metabolism in mice and humans
Ma, S., Dubin, A. E., Zhang, Y., Mousavi, S. A. R., Wang, Y., Coombs, A. M., Loud, M., Andolfo, I., & Patapoutian, A. (2021) · Cell · doi:10.1016/j.cell.2021.01.024 · Cited by 232
Metadata
- Authors
- Taher, A. T., & Saliba, A. N.
- Venue
- Hematology
- Publisher
- American Society of Hematology
- Published
- 2017-12-08
- Volume
- 2017
- Issue
- 1
- Pages
- 265-271
- ISSN
- 1520-4383 (ISSN-L)
- 1520-4391
- OpenAlex
- W2777414596
- Cited by
- 355
- References
- 52
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.